Literature DB >> 18502785

Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males.

Felix J Bode1, Michael Stephan, Hendrik Suhling, Reinhard Pabst, Rainer H Straub, Kerstin A Raber, Michael Bonin, Huu Phuc Nguyen, Olaf Riess, Andreas Bauer, Charlotte Sjoberg, Asa Petersén, Stephan von Hörsten.   

Abstract

Recent clinical studies have highlighted that female sex hormones represent potential neuroprotective mediators against damage caused by acute and chronic brain diseases. This evidence has been confirmed by experimental studies documenting the protective role of female sex hormones both in vitro and in vivo, although these studies did not specifically focus on Huntington's disease (HD). We therefore investigated the onset and course of HD in female and male transgenic (tg) HD (CAG(n51)) and control rats across age and focused on three aspects: (i) behavioral and physiological alterations (energy expenditure, home-cage activity, emotional disturbance and motor dysfunction), (ii) morphological markers (numbers and characteristics of striatal DARPP32(+) medium-sized spiny neurons (MSNs) and dopamine receptor autoradiography) and (iii) peripheral sex hormone levels as well as striatal estrogen receptor expression. Independent of their sex, tgHD rats exhibited increased levels of food intake, elevated home-cage activity scores and anxiolytic-like behavior, whereas only males showed an impairment of motor function. In line with the latter finding, loss and atrophy of DARPP32(+) MSNs were apparent only in male tgHD rats. This result was associated with a decreased striatal dopamine D1 receptor density and lower plasma levels of 17beta-estradiol at the age of 14 months. As DARPP32(+) MSNs expressed both alpha- and beta-estrogen receptors and showed a correlation between cell numbers and 17beta-estradiol levels, our findings suggest sex-related differences in the HD phenotype pointing to a substantial neuroprotective effect of sex hormones and opening new perspectives on the therapy of HD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502785     DOI: 10.1093/hmg/ddn159

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  40 in total

1.  Substance abuse may be a risk factor for earlier onset of Huntington disease.

Authors:  Joanne A Byars; Leigh J Beglinger; David J Moser; Pedro Gonzalez-Alegre; Peg Nopoulos
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

2.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

Review 3.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

4.  Sex-dependent behavioral impairments in the HdhQ350/+ mouse line.

Authors:  Jessica K Cao; Peter J Detloff; Richard G Gardner; Nephi Stella
Journal:  Behav Brain Res       Date:  2017-09-18       Impact factor: 3.332

5.  Estrogen or estrogen receptor agonist inhibits lipopolysaccharide induced microglial activation and death.

Authors:  Joshua A Smith; Arabinda Das; Jonathan T Butler; Swapan K Ray; Naren L Banik
Journal:  Neurochem Res       Date:  2010-12-03       Impact factor: 3.996

6.  Differential effects of SNARE-dependent gliotransmission on behavioral phenotypes in a mouse model of Huntington's disease.

Authors:  Annesha C King; Tara E Wood; Efrain Rodriguez; Vladimir Parpura; Michelle Gray
Journal:  Exp Neurol       Date:  2020-05-07       Impact factor: 5.330

Review 7.  Beyond the rat models of human neurodegenerative disorders.

Authors:  Ondrej Bugos; Mangesh Bhide; Norbert Zilka
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

8.  Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease.

Authors:  Benjamin R Miller; Adam G Walker; Stephen C Fowler; Stephan von Hörsten; Olaf Riess; Michael A Johnson; George V Rebec
Journal:  Neurobiol Dis       Date:  2009-10-08       Impact factor: 5.996

9.  AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease.

Authors:  B Connor; Y Sun; D von Hieber; S K Tang; K S Jones; C Maucksch
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

10.  Huntingtin polyQ Mutation Impairs the 17β-Estradiol/Neuroglobin Pathway Devoted to Neuron Survival.

Authors:  Maria Teresa Nuzzo; Marco Fiocchetti; Pierangela Totta; Mariarosa A B Melone; Antonella Cardinale; Francesca R Fusco; Stefano Gustincich; Francesca Persichetti; Paolo Ascenzi; Maria Marino
Journal:  Mol Neurobiol       Date:  2016-12-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.